We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information
Medications are available that can slow the progression of melanoma. However, not all melanomas respond, and the side effects sometimes outweigh the benefits.
That’s why researchers are working hard to develop more options—like those under investigation in our clinical research program.
On this page you’ll find information about melanoma clinical trials in general, the current treatment landscape, and active clinical trials for melanoma, including stage III (stage 3) melanoma and stage IV (stage 4) melanoma (also called advanced or metastatic melanoma).
Watch our short video to find out more about melanoma and why we are conducting clinical research into the condition.
Clinical trials in detail
Our "Participant's Discussion Guide to Cancer Clinical Trials" has information about how clinical trials work.
Discussing melanoma with your doctor
Topics you might want to discuss with your doctor,
Thank you for considering a melanoma clinical trial
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
A Study to Assess DF6002 (BMS-986415) Alone and in Combination With Nivolumab in Participants With Locally Advanced or Metastatic Solid Tumors
A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma
Hear from patients with melanoma as they share experiences
We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information